Novartis Investigative Site

Duluth, Georgia 30096

0 studies enrolling now · 5 studies all time

What they study most

Ankylosing Spondylitis, Atherosclerosis, Chronic Obstructive Pulmonary Disease, Psoriatic Arthritis

Studies at this site

• Study Estimating the Clinical Difference Between 300 mg and 150 mg of Secukinumab Following Dose Escalation to 300 mg in Patients With Ankylosing Spondylitis — Completed
• Study to Evaluate the Safety and Efficacy of Secukinumab 300 mg and 150 mg in Adult Patients With Active Psoriatic Arthritis (PsA) After 16 Weeks of Treatment Compared to Placebo — Completed
• Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events) — Completed
• Efficacy and Safety Study of QVA149 in COPD Patients — Completed
• 1-year Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Chronic Obstructive Pulmonary Disease (COPD) — Completed